Format

Send to

Choose Destination
See comment in PubMed Commons below
Palliat Med. 2014 Apr 22;28(7):990-991. [Epub ahead of print]

The use of aprepitant in a case of refractory nausea and vomiting.

Author information

  • 1St Benedict's Hospice, Sunderland, UK.
  • 2St Benedict's Hospice, Sunderland, UK mark.lee@stft.nhs.uk.

Abstract

BACKGROUND:

This case report describes a patient whose refractory nausea and vomiting significantly improved with the use of aprepitant, a neurokinin receptor antagonist currently only licensed for short-term use in chemotherapy-induced nausea and vomiting.

CASE PRESENTATION:

A patient with breast cancer and meningeal metastases had an 18-month history of nausea and vomiting refractory to a number of antiemetics commonly used in palliative care. The nausea and vomiting resolved after receiving two doses of the drug aprepitant.

CASE MANAGEMENT AND OUTCOME:

Maintenance antiemetic treatment with aprepitant was continued over a 5-month period with no recurrence of nausea and vomiting, and no observed side effects.

CONCLUSIONS:

Aprepitant has a potential role as an antiemetic for refractory symptoms within the palliative-care setting.

© The Author(s) 2014.

KEYWORDS:

Aprepitant; nausea; neurokinin receptor antagonist; refractory; vomiting

[PubMed - as supplied by publisher]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk